The Future of
We have provided three foundational models which will serve as the basis for expansion to additional market opportunities and patient populations.
Nu-V3 Market Models
Our Preferred Provider Network will offer both existing patients the opportunity to access the Nu-V3 program, as well as those new patients who are interested in Nu-V3 but are looking for a provider.
In 2023, patients themselves will be able to access the Nu-V3 program, utilizing our E-scripts system and remote treatment monitoring.
Our Nu-V3 Corporate Network offers employers access to the Nu-V3 program in a way that allows members of employees to experience Nu-V3 with no disruption in their daily routine.
Initiatives for 2023
Nu-V3 initiatives are clinical programs designed to treat those in need, demonstrate the safety, effectiveness and ease of use for Nu-V3 and create demand as we prepare for market entry.
Veterans and first responders are at the very forefront of our H.O.P.E. Initiative. Our plan to get Nu-V3 to a significant number of these champions is dynamic and lead by the Nu-Life Executive Medical Team member most qualified for this initiative.
The Opioid Dependent
Those that have become reliant and dependent upon addictive medications, especially opioids, are at the very heart of our effort to improve the lives of those we treat, for the better. Addiction knows no boundary and runs through every patient population we are treating.
Chronic Symptom Sufferers
With 1.2 billion people suffering from chronic symptoms worldwide and getting worse by the day, it goes without saying that we are dedicated to serving this patient population and treating the greatest number of people as quickly as possible.
Nu-V3 initiatives for expanded uses are designed to treat those in need, demonstrate the safety, effectiveness and ease of use for Nu-V3 and creating demand as we prepare for market entry.
The Nu-Life Medical Alliance is focused on these new uses as we enter the market for symptom management.